retatrutide do is a new weight-loss injection, which is currently in its final stages of safety and efficacy trials. UK approval is likely in 2027, pending full MHRA review. Developed by Eli Lilly Retatrutide: The New Triple-Agonist Weight

Retatrutide is a GLP-1, like Wegovy and Zepbound, and a GIP (glucose-dependent insulinotropic polypeptide), like Zepbound, but it also includes a hormone that none of the other weight loss drugs on the market have: glucagon, a hormone produced by the pancreas that raises blood sugar levels to prevent them from dropping too low

the sulphydryl and -glutamyl groups) it may to some extent compensate for glutathione in the cellular defence against oxidative stress

Other sources suggest that an increase in appetite may occur, and a rash

However, differences in trial design and patient backgrounds, such as baseline A1C and concurrent use of metformin, make direct comparisons challenging